SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 31.88 |
| Enterprise Value ($M) | -4.75 |
| Book Value ($M) | 34.30 |
| Book Value / Share | 1.09 |
| Price / Book | 0.93 |
| NCAV ($M) | 34.30 |
| NCAV / Share | 1.09 |
| Price / NCAV | 0.93 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.79 |
| Return on Assets (ROA) | -0.50 |
| Return on Equity (ROE) | -0.54 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 6.63 |
| Current Ratio | 6.63 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 40.39 |
| Assets | 40.39 |
| Liabilities | 6.09 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D | Foundation Fighting Blindness Retinal Degeneration Fund | 8.16 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 36,156 | 215,442 | 16.78 | |
| 41,289 | 285,310 | 14.47 | |
| 25,076 | 79,771 | 31.43 | |
| 49,608 | 187,610 | 26.44 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| INM – InMed Pharmaceuticals Inc. | INMB – INmune Bio, Inc. |
| INTS – Intensity Therapeutics, Inc. | ITRM – Iterum Therapeutics plc |
| JAGX – Jaguar Health, Inc. |
Financial data and stock pages provided by
Fintel.io